Avacta Group and LG Chem Life Sciences announced a multi-target collaboration and development agreement. The agreement provides LG Chem with the exclusive rights to develop and commercialize, on a worldwide basis, multiple Affimer® therapeutics intended for treatment of patients in the fields of inflammatory disorders, and oncology.    Under the terms of the agreement, Avacta will generate and carry out the discovery, optimization and protein engineering of Affimer® drug candidates again...